Skip to main content
SpringerLink
Log in

Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate the effects of the selective oestrogen receptor modulator, raloxifene, and those of statin, atorvastatin, in reducing the cardiovascular risks associated with the post-menopausal status. A detailed study of serum lipid concentrations was performed in four groups of post-menopausal women receiving either placebo, raloxifene or atorvastatin alone or their combination for the period of three months.

Group A (raloxifene) showed significant decrease in total cholesterol levels (P < 0.05) and an increase in phospholipids concentration (P < 0.05), followed by a marked reduction in low-density lipoprotein cholesterol (LDL-C) levels (P < 0.01) and ApoB amounts (P < 0.001). Additionally, ApoA-I concentration was significantly increased (P < 0.01).

Group B (atorvastatin) presented decreased cholesterol (P < 0.05) and triglycerides levels (P < 0.01), followed by elevated high-density lipoprotein cholesterol (HDL-C) concentration (P < 0.05) and low LDL-C amounts (P < 0.001). ApoA-I was significantly increased (P < 0.001) whereas ApoB was reduced (P < 0.001).

The combined treatment in Group C (raloxifene and atorvastatin) showed significant changes in the majority of serum lipids. In particular, total cholesterol was reduced (P < 0.001), as well as triglycerides (P < 0.001) levels. Phospholipids were raised (P < 0.01) whereas LDL-C was reduced (P < 0.001) as was ApoB (P < 0.001). Furthermore, ApoA-I was elevated (P < 0.001). A further attempt to evaluate each treatment group was performed and the significance of these results is discussed. (Mol Cell Biochem 261: 71–75, 2004)

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kannel WB, Hjortland MC, McNamara PM, Gordon T: Menopause and risk of cardiovascular disease: The Framingham Study. Ann Inter Med 85: 447–452, 1976

    CAS  Google Scholar 

  2. Colditz GA, Willett WC, Stampfer MJ, Rosner BS, Speizer FE, Hennekens CH: Menopause and the risk of coronary heart disease in women. N Engl J Med 316: 1105–1110, 1987

    CAS  PubMed  Google Scholar 

  3. Bryant HU, Dere WH: Selective estrogen receptor modulators: An alternative to hormone replacement therapy. Proc Soc Exp Biol Med 217: 45–52, 1998

    CAS  PubMed  Google Scholar 

  4. Umland EM, Rinaldi C, Parks SM, Boyce EG: The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Ann Pharmacother 33: 1315–1328, 1999

    CAS  PubMed  Google Scholar 

  5. Agnusdei D, Liu-Leage S, Augendre-Ferrante B: Results of international clinical trials with raloxifene. Ann Endocrinol 60: 242–246, 1999

    CAS  Google Scholar 

  6. Kauffman RF, Bryant HU: Selective estrogen receptor modulators. Drugs New Perspect 8: 531–539, 1995

    Google Scholar 

  7. Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an oestrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science 273: 1222–1225, 1996

    CAS  PubMed  Google Scholar 

  8. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL: Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Min Res 13: 1747–1754, 1998

    CAS  Google Scholar 

  9. Park L, Evans MF: Raloxifene: Designer estrogen for preventing postmenopausal osteoporosis. Can Fam Phys 45: 1191–1193, 1999

    CAS  Google Scholar 

  10. Draper MW, Flowers DE, Huster WJ, Neild JA: Effects of raloxifene (LY139481) HCl on biochemical markers of bone and lipid metabolism in healthy postmenopausal women. In: C. Christiansen and B. Riis (eds). Proceedings 1993: Fourth International Symposium on Osteoporosis and Consensus Development Conference, Handelstrykkeriet Aalborg ApS, Aalborg, Denmark, 1993, pp. 119–121

    Google Scholar 

  11. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud CA: Controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Min Res 11: 835–842, 1996

    CAS  Google Scholar 

  12. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW: Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 279: 1445–1451, 1998

    Article  CAS  Google Scholar 

  13. Boyack M, Lookinland S, Chasson S: Efficacy of raloxifene for treatment of menopause: A systematic review. J Am Acad Nurse Pract 14: 150–165, 2002

    PubMed  Google Scholar 

  14. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622, 1998

    CAS  Google Scholar 

  15. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, Wilhelmsen L, Haghfelt T, Thorgeirsson G, Pyorala K, Miettinen T, Christophersen B, Tobert JA, Musliner TA, Cook TJ: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 97: 1453–1460, 1998

    CAS  PubMed  Google Scholar 

  16. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335: 1001–1009, 1996

    Article  CAS  PubMed  Google Scholar 

  17. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301–1307, 1995

    Article  CAS  PubMed  Google Scholar 

  18. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis 164: 361–369, 2002

    Article  CAS  PubMed  Google Scholar 

  19. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ: Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 43: 1701–1707, 2002

    CAS  PubMed  Google Scholar 

  20. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 158: 407–416, 2001

    Article  CAS  PubMed  Google Scholar 

  21. Hunninghake D, Insull W, Knopp R, Davidson M, Lohrbauer L, Jones P, Kafonek S: Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol 88: 635–639, 2001

    CAS  PubMed  Google Scholar 

  22. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, Thillet J: Atorvastatin lowers lipoprotein (a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 164: 305–311, 2002

    Article  CAS  PubMed  Google Scholar 

  23. Paolisso G, Barbagallo M, Petrella G, Ragno E, Barbieri M, Giordano M, Varricchio M: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 150: 121–127, 2000

    Article  CAS  PubMed  Google Scholar 

  24. Friedewald WT, Levy RI, Fredrickso S: Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18: 499–502, 1972

    CAS  PubMed  Google Scholar 

  25. Yamaguchi Y: Determination of high-density lipoprotein phospholipids in serum. Clin Chim Acta 26: 1275–1277, 1980

    CAS  Google Scholar 

  26. Insull W, Kafonek S, Goldner D, Zieve F, for the ASSET Investigators: Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. Am J Cardiol 87: 554–559, 2001

    Article  CAS  PubMed  Google Scholar 

  27. Schweitzer M, Tessier D, Vlahos WD, Leite L, Collet JP, McQueen MJ, Harvey L, Alaupovic P: A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis 162: 201–210, 2002

    Article  CAS  PubMed  Google Scholar 

  28. Giral P, Bruckert E, Jacob N, Chapman MJ, Foglietti MJ, Turpin G: Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 154: 421–427, 2001

    Article  CAS  PubMed  Google Scholar 

  29. Kakafika A, Tsimihodimos V, Elisaf M: Effect of atorvastatin on serum uric acid levels. Atherosclerosis 158: 255, 2001

    Article  CAS  PubMed  Google Scholar 

  30. Kakafika A, Liamis G, Elisaf M, Mikhailidis D: Effect of atorvastatin on serum creatinine levels. Curr Med Res Opin 17: 230–231, 2001

    Article  CAS  PubMed  Google Scholar 

  31. Rosenson RS, Tangney CC: Anti-atherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 279: 1643–1650, 1998

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Chemistry, School of Medicine, University of Athens, Athens, Greece

    Christina Piperi, Christos Kalofoutis, Irene Lagogianni, George Troupis & Anastasios Kalofoutis

Authors
  1. Christina Piperi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christos Kalofoutis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irene Lagogianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. George Troupis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anastasios Kalofoutis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Piperi, C., Kalofoutis, C., Lagogianni, I. et al. Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women. Mol Cell Biochem 261, 71–75 (2004). https://doi.org/10.1023/B:MCBI.0000028739.10079.0b

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:MCBI.0000028739.10079.0b

Search

Navigation